Yasaman Taheri1,2, Nataša Joković3, Jelena Vitorović3, Oliver Grundmann4,5, Alfred Maroyi6, Daniela Calina7. 1. Phytochemistry Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 2. Department of Pharmacology and Toxicology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 3. The Faculty of Science and Mathematics, University of Niš, Niš, Serbia. 4. Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL, United States. 5. Department of Biobehavioral Nursing Science, College of Nursing, University of Florida, Gainesville, FL, United States. 6. Department of Botany, University of Fort Hare, Alice, South Africa. 7. Department of Clinical Pharmacy, University of Medicine and Pharmacy of Craiova, Craiova, Romania.
Abstract
Background: Infection is a disease that can occur due to the entrance of a virus, bacteria, and other infectious agents. Cefiderocol is innovative cephalosporin drug that belongs to a special class of antibiotics, sideromycins, which are taken up by bacterial cells through active transport. The unique cell entry and stability to β-lactamases allow cefiderocol to overcome the most common resistance mechanisms in Gram-negative bacteria. Objective: This article aims to highlight the therapeutic efficacy, safety and tolerability of cefiderocol, with a focus on the FDA label. Methods: The pharmacological properties of cefiderocol are also summarized. In this review, we conducted literature research on the PubMed database using the following keywords: "antimicrobial treatment", "new antibiotic", "cefiderocol", "siderophore cephalosporin"; "multidrug-resistant", "Gram-negative bacilli", "critically ill patients"; "severe bacterial infections". Results: There were identified the most relevant data about the pathophysiology of serious bacterial infections, antibacterial mechanism of action, microbiology, mechanisms of resistance, pharmacokinetic and pharmacodynamic properties of cefiderocol. Conclusion: The results highlighted there appeared to be clinical benefit from cefiderocol in the treatment of infections caused by Gram-negative aerobic microorganisms in adult patients with severe infections and limited treatment options.
Background: Infection is a disease that can occur due to the entrance of a virus, bacteria, and other infectious agents. Cefiderocol is innovative cephalosporin drug that belongs to a special class of antibiotics, sideromycins, which are taken up by bacterial cells through active transport. The unique cell entry and stability to β-lactamases allow cefiderocol to overcome the most common resistance mechanisms in Gram-negative bacteria. Objective: This article aims to highlight the therapeutic efficacy, safety and tolerability of cefiderocol, with a focus on the FDA label. Methods: The pharmacological properties of cefiderocol are also summarized. In this review, we conducted literature research on the PubMed database using the following keywords: "antimicrobial treatment", "new antibiotic", "cefiderocol", "siderophore cephalosporin"; "multidrug-resistant", "Gram-negative bacilli", "critically illpatients"; "severe bacterial infections". Results: There were identified the most relevant data about the pathophysiology of serious bacterial infections, antibacterial mechanism of action, microbiology, mechanisms of resistance, pharmacokinetic and pharmacodynamic properties of cefiderocol. Conclusion: The results highlighted there appeared to be clinical benefit from cefiderocol in the treatment of infections caused by Gram-negative aerobic microorganisms in adult patients with severe infections and limited treatment options.
Authors: Patricia J Simner; Stephan Beisken; Yehudit Bergman; Michael Ante; Andreas E Posch; Pranita D Tamma Journal: Microb Drug Resist Date: 2021-10-06 Impact factor: 3.431
Authors: Rajib Hossain; Cristina Quispe; Jesús Herrera-Bravo; Md Shahazul Islam; Chandan Sarkar; Muhammad Torequl Islam; Miquel Martorell; Natália Cruz-Martins; Ahmed Al-Harrasi; Ahmed Al-Rawahi; Javad Sharifi-Rad; Manshuk Ibrayeva; Sevgi Durna Daştan; Mohammed M Alshehri; Daniela Calina; William C Cho Journal: Oxid Med Cell Longev Date: 2021-12-28 Impact factor: 6.543
Authors: Muhammad Torequl Islam; Cristina Quispe; Dina M El-Kersh; Manik Chandra Shill; Kanchan Bhardwaj; Prerna Bhardwaj; Javad Sharifi-Rad; Miquel Martorell; Rajib Hossain; Ahmed Al-Harrasi; Ahmed Al-Rawahi; Monica Butnariu; Lia Sanda Rotariu; Hafiz Ansar Rasul Suleria; Yasaman Taheri; Anca Oana Docea; Daniela Calina; William C Cho Journal: Oxid Med Cell Longev Date: 2021-12-10 Impact factor: 6.543
Authors: Javad Sharifi-Rad; Cristina Quispe; Muhammad Imran; Abdur Rauf; Muhammad Nadeem; Tanweer Aslam Gondal; Bashir Ahmad; Muhammad Atif; Mohammad S Mubarak; Oksana Sytar; Oxana Mihailovna Zhilina; Ekaterina Robertovna Garsiya; Antonella Smeriglio; Domenico Trombetta; Daniel Gabriel Pons; Miquel Martorell; Susana M Cardoso; Ahmad Faizal Abdull Razis; Usman Sunusi; Ramla Muhammad Kamal; Lia Sanda Rotariu; Monica Butnariu; Anca Oana Docea; Daniela Calina Journal: Oxid Med Cell Longev Date: 2021-07-19 Impact factor: 6.543